Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) had its target price hoisted by analysts at Maxim Group from $10.00 to $11.00 in a research note issued to investors on Friday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s target price would suggest a potential upside of 147.19% from the company’s previous close.

The analysts wrote, “Sonoma reported F2Q18 (fiscal YE Mar. 31) results; total product sales were $4.1M, up from the prior period driven by organic growth in Alevicyn, Celacyn and Mondoxyne. Dermatology revenues were up 36% versus prior quarter (June 2017), and scripps growth up 14% (Sept. quarter versus June) and 24% versus the March quarter. The company reported an operational loss of $2.8M and ended the period with $10M in cash, runway to support the company as sales climb and they push towards positive free cash flow. Business Highlights:.””

Separately, ValuEngine cut shares of Sonoma Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st.

Sonoma Pharmaceuticals (NASDAQ SNOA) traded down $0.24 during midday trading on Friday, reaching $4.45. 78,843 shares of the company’s stock traded hands, compared to its average volume of 33,071. Sonoma Pharmaceuticals has a 1 year low of $4.16 and a 1 year high of $8.25. The company has a quick ratio of 5.68, a current ratio of 6.48 and a debt-to-equity ratio of 0.02.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last posted its earnings results on Tuesday, August 8th. The company reported ($0.82) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.09). Sonoma Pharmaceuticals had a negative return on equity of 44.24% and a net margin of 54.36%. The firm had revenue of $3.84 million during the quarter. equities analysts expect that Sonoma Pharmaceuticals will post -3 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/10/sonoma-pharmaceuticals-inc-snoa-earns-buy-rating-from-maxim-group.html.

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. Janus Capital Management LLC raised its holdings in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 41.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 37,926 shares of the company’s stock after buying an additional 11,053 shares during the period. Janus Capital Management LLC owned about 0.89% of Sonoma Pharmaceuticals worth $272,000 as of its most recent SEC filing. Institutional investors and hedge funds own 9.72% of the company’s stock.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.

Receive News & Ratings for Sonoma Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.